PDCD1 and glioma: Overall, this study is the first to discover that the combination of sodium butyrate with an anti-PD-1 antibody demonstrates significant potential in treating gliomas by modulating immune responses and affecting gut microbiota, providing insights into overcoming the limitations of current glioma clinical treatments.